Uniphar plc

Equities

UPR

IE00BJ5FQX74

Pharmaceuticals

Market Closed - Irish S.E. 12:55:00 2024-03-28 pm EDT 5-day change 1st Jan Change
2.6 EUR +0.78% Intraday chart for Uniphar plc -0.38% -3.70%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Uniphar ups full-year dividend as profit falls but revenue climbs AN
Uniphar Seeks M&A CI
Transcript : Uniphar plc, 2023 Earnings Call, Feb 27, 2024
Uniphar's FY23 Profit Edges Down; Revenue Grows MT
Earnings Flash (UPR.L) UNIPHAR Reports FY23 EPS EUR0.16 MT
Uniphar plc Recommends Final Dividend, Payable on 14 May 2024 CI
Uniphar plc Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Uniphar set to meet annual profit and earnings expectations AN
Uniphar plc Announces Executive Changes CI
Uniphar plc Announces Resignation of Jeffrey Berkowitz from the Board CI
Uniphar non-exec director buys EUR115,000 worth of shares AN
Uniphar non-exec chair buys EUR200,000 worth of shares AN
Uniphar executives Rabbette and Dolphin buy shares AN
Uniphar revenue up on divisional growth; sets out earnings target AN
Transcript : Uniphar plc, H1 2023 Earnings Call, Sep 14, 2023
Uniphar Posts Drop in H1 Attributable Profit; Revenue Rises MT
Earnings Flash (UPR.L) UNIPHAR Reports H1 Revenue EUR1.24B MT
Earnings Flash (UPR.L) UNIPHAR Reports H1 EPS EUR0.06 MT
Uniphar plc Reports Earnings Results for the Half Year Ended June 30, 2023 CI
Uniphar plc Declares Interim Dividend for the Period to 30 June 2023, Payable on 20 October 2023 CI
Uniphar Group Appoints Kay Bonavita as Chief Commercial Officer for Uniphar Logistics to Lead the US Team Based Out of Raleigh, North Carolina CI
FTSE 100 Closes Down 0.2% as Miners Offset Ocado, Rolls-Royce Jumps DJ
Uniphar half-year trading in line with expectations AN
Uniphar Sees Over 5% Uptick in H1 Organic Gross Profit MT
FTSE 100 Closes Thursday Down 0.1% After BOE Rate Hike DJ
Chart Uniphar plc
More charts
Uniphar plc is a diversified healthcare services business servicing the requirements of more than 200 multinational pharmaceutical and medical technology manufacturers across three divisions - Commercial & Clinical, Product Access and Supply Chain & Retail. With a workforce of more than 2,800, the Group is active in Ireland, the United Kingdom, the Benelux, the Nordics, Germany and the United States. The Company's vision is to improve patient access to pharmaco-medical products and treatments by enhancing connectivity between manufacturers and healthcare stakeholders. Uniphar plc represents a strong combination of scale, growth and profitability.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
2.6 EUR
Average target price
4.329 EUR
Spread / Average Target
+66.48%
Consensus
  1. Stock
  2. Equities
  3. Stock Uniphar plc - Irish S.E.
  4. News Uniphar plc
  5. Uniphar : Keeps Medium-Term Goals On Strong Momentum In H1